Johnson & Johnson





Real-time Estimate Cboe BZX 11:43:08 2023-12-08 am EST Intraday chart for Johnson & Johnson 5-day change 1st Jan Change
153.96 USD -0.93% -2.78% -12.84%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Retreating Late Afternoon MT
Sector Update: Health Care Stocks Drop Thursday Afternoon MT
Top Stories at Midday: Moody's Downgrades Chinese Banks; AbbVie Acquires Cerevel; Washington to Use March-In Law to Seize Pharma Patents; JetBlue Hikes Outlook MT
Biden Administration Launches Measures to Cut Health Care Costs; Proposes Use of 'March-In Rights' for Drugs MT
President Biden Announces Health Care Measure to Lower Costs, Promote Competition, 'March-In' Drug Patents on Govt-Funded Research MT
Vanda Pharmaceuticals Buys Rights to Multiple Sclerosis Drug Ponvory for $100 Million MT
Global markets live: Mastercard, Diageo, Nvidia, Airbnb, Exxon Mobil...
Job losses delight investors
RBC Raises Price Target on Johnson & Johnson to $181 From $178, 'Encouraged' by Enterprise Business Review, Keeps Outperform Rating MT
J&J says it has settled some talc claims, will continue bankruptcy strategy RE
Trending : Johnson & Johnson Sees Sales Growth for 2024 and Beyond DJ
Johnson & Johnson forecasts as much as 6% sales growth in 2024 RE
Global markets live: AT&T, Blackstone, GM, Take-Two, CVS Health...
Transcript : Johnson & Johnson - Special Call CI
Anything is possible
Johnson & Johnson forecasts as much as 6% sales growth in 2024 RE
Johnson & Johnson: long-term objectives unveiled CF
Johnson & Johnson Provides 2024 Outlook MT
Johnson & Johnson Targets Sales Growth in Years Ahead DJ
Johnson & Johnson Provides Earnings Guidance for 2024 CI
Sanofi CEO under pressure to woo investors after spending shock RE
Model N: A niche positioning
Tech firms, Wall Street lead job cuts in Corporate America RE
UBS Upgrades Johnson & Johnson to Buy From Neutral, Raises Price Target to $180 From $167 MT
Johnson & Johnson: the stock benefits from a positive opinion from UBS CF
Chart Johnson & Johnson
More charts
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
More Ratings
Mean consensus
Number of Analysts
Last Close Price
Average target price
Spread / Average Target
1st Jan change Capi.
-12.84% 374 B $
+60.22% 529 B $
+42.56% 430 B $
-7.13% 263 B $
-7.65% 261 B $
+1.21% 198 B $
-9.95% 197 B $
-43.79% 162 B $
+2.66% 145 B $
-4.13% 115 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Johnson & Johnson - Nyse
  4. News Johnson & Johnson
  5. Johnson & Johnson, Procter & Gamble Sued in Florida Over Decongestant Cold Medicines
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration